Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STOCKWATCH: Alien invasions and base behavior in genomics

This article was originally published in Scrip

Executive Summary

In the past few days it has become clear that the original $118 million bid for Californian genome sequencing firm Complete Genomics by China's BGI-Shenzhen was trumped by a $124 million bid from another US sequencing technology company Illumina. The higher bid was subsequently rejected by the Complete Genomics board, possibly because the company did not want to risk the use of a $30 million bridging loan that followed the signing of the merger agreement. Complete Genomics has argued in its SEC filings that the unsolicited offer from Illumina did not constitute ‘a Superior Proposal’ to BGI’s offer despite being worth 5% more because “among other reasons, there is a substantial likelihood that any transaction […] would fail to receive antitrust clearance.”

You may also be interested in...

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.

Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors

Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.

Stockwatch: Batsu Games − Drug And Vaccine Development

Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts